Talk:Daiichi Sankyo

Removed the erranous food/beverage analogy.
It doesn't belong in an encyclopedia entry for this company Brettgo1 12:51, 22 October 2006 (UTC)

WikiProject class rating
This article was automatically assessed because at least one WikiProject had rated the article as stub, and the rating on other projects was brought up to Stub class. BetacommandBot 14:54, 9 November 2007 (UTC)

Combination Therapies missing from Product list
Products like Azor and Trivasc (CS-8635) (still pending FDA approval in US) should be be included in the product line up. Perhaps as a sub-bullet of Benicar, as they are derivatives of Benicar.

Also recently, DSI launched in Japan (4/16) Rezaltas (I think this is Trivasc from the description, not sure though). Can someone more knowledgeable confirm this? http://www.daiichisankyo.com/news/2010_04_16_242e2.pdf

Misosoup7 (talk) 21:18, 6 May 2010 (UTC)

Official Pronunciation of Company Name
I made a change in the romanization of the company's name. In normal Japanese, the word for "Ltd" or "Inc" is pronounced "kabushiki-gaisha". However, after research I found that, in company names, the pronunciation "-kaisha" is also common. Regrettably, although I searched web pages in English as well as in Japanese, I was unable to find any info on this matter concerning this particular company. Ceartaigh (talk) 17:31, 29 March 2019 (UTC)

COI edit requests
Hi! I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I'd like to request some updates to this article:

Lead

 * In infobox, adding "Ken Keller (President and CEO, Daiichi Sankyo, Inc.) " under "Key people". (Also, FYI, I previously updated the CEO listed in the infobox with ref, as I figured that would qualify as WP:COIU.)
 * Also in infobox, updating financial figures and number of employees per latest annual report:
 * |num_employees = 15,348 (as of March 2020)
 * |revenue      = ▲ $ 9.028 billion USD (FY 2019)

(¥ 981.8 billion JPY) (FY 2019)
 * |net_income   = ▲ $ 1.276 billion USD (FY 2019)

(¥ 138.8 billion JPY) (FY 2019)
 * I did the USD/JPY conversion using the average annual exchange rate identified on page 90 of the report: 108.75.


 * Updating "It achieved JPY 2,305.4 billion in revenue in 2018." to "It achieved JPY 981.8 billion in revenue in 2019."
 * In third sentence, adding "American pharmaceutical company American Regent" to the list of subsidiaries, per the first suggested addition to "History" below.

History

 * Adding to first paragraph:
 * Tweaking the opening of "Kickbacks" from  to
 * In "Kickbacks", after  adding   (per the source cited).
 * Adding after the U3 Pharma mention in "Acquisitions" (or as a new "Recent history" subsection?):
 * Adding to "Acquisitions":
 * Adding to end of "Acquisitions" (or as a new "Recent history" subsection?):

Products
Updating the list accordingly:
 * Merging the two lists, since there are no sources provided for the division (nor is this how the company divides its products)
 * Deleting redundant "win bp piramal" item
 * Deleting, adding, and combining items to reflect the current product list
 * Adding refs for each item, as well as a ref to the comprehensive list on Daiichi's web site

Sankyo Oncology

 * Enhertu (trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki in the United States only)
 * Turalio (pexidartinib)
 * Vanflyta (quizartinib) (available only in Japan)
 * Azor (amlodipine olmesartan medoxomil)
 * Mevalotin (pravastatin)
 * Loxonin (loxoprofen)
 * Hirudoid (a heparinoid preparation)
 * Olmetec (olmesartan)
 * Captopril
 * win bp piramal (olmesartan medoxomil)
 * Panipenem

Daiichi Pharmaceutical Cardiovascular

 * Cravit (levofloxacin)
 * Evoxac (cevimeline)
 * Floxin Otic (ofloxacin)
 * Gracevit (sitafloxacin, only sold in Japan)
 * Oflovid (ofloxacin, only sold in Taiwan and Vietnam under license to Santen)
 * Lixiana/Savaysa (edoxaban)
 * Minnebro (esaxerenone) (available only in Japan)
 * Benicar (olmesartan medoxomil) (also sold as Benicar HCT, Azor, Olmetec, Rezaltas, Sevikar, and Tribenzor)
 * Effient (prasugrel) (co-marketed with Eli Lilly and Company ; also sold as Efient )
 * Nilemdo (bempedoic acid, only sold in the EU) (also sold as Nustendi)

Daiichi Pharmaceutical Other

 * Canalia (teneligliptin, canagliflozin) (available only in Japan)
 * Evoxac (cevimeline hydrochloride)
 * Injectafer (ferric carboxymaltose injection)
 * Memary (memantine hydrochloride) (available only in Japan)
 * Nexium (esomeprazole) (only in Japan; marketed by AstraZeneca elsewhere)
 * Pralia (denosumab) (only available in Japan; also sold there as Ranmark )
 * Tarlige (mirogabalin) (only available in Japan)
 * Tenelia (teneligliptin hydrobromide hydrate)
 * Venofer (iron sucrose)
 * Vimpat (lacosamide) (only available in Japan; co-marketed with UCB)
 * WelChol Welchol (colesevelam HCl)
 * Zelboraf (vemurafenib)

Oncology

 * Enhertu (trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki in the United States only)
 * Turalio (pexidartinib)
 * Vanflyta (quizartinib) (available only in Japan)

Cardiovascular

 * Lixiana/Savaysa (edoxaban)
 * Minnebro (esaxerenone) (available only in Japan)
 * Benicar (olmesartan medoxomil) (also sold as Benicar HCT, Azor, Olmetec, Rezaltas, Sevikar, and Tribenzor)
 * Effient (prasugrel) (co-marketed with Eli Lilly and Company; also sold as Efient)
 * Nilemdo (bempedoic acid, only sold in the EU) (also sold as Nustendi)

Other

 * Canalia (teneligliptin, canagliflozin) (available only in Japan)
 * Evoxac (cevimeline hydrochloride)
 * Injectafer (ferric carboxymaltose injection)
 * Memary (memantine hydrochloride) (available only in Japan)
 * Nexium (esomeprazole) (only in Japan; marketed by AstraZeneca elsewhere)
 * Pralia (denosumab) (only available in Japan; also sold there as Ranmark )
 * Tarlige (mirogabalin) (only available in Japan)
 * Tenelia (teneligliptin hydrobromide hydrate)
 * Venofer (iron sucrose)
 * Vimpat (lacosamide) (only available in Japan; co-marketed with UCB)
 * Welchol (colesevelam HCl)
 * Zelboraf (vemurafenib)

Pipeline candidates
Updating outdated subsection entirely (tivantinib is no longer in the pipeline, mirogabalin is an approved product (Tarlige), and trials of SUN13837 have been discontinued):

Select investigational candidates in Daiichi Sankyo's pipeline include:
 * Datopotamab deruxtecan (Dato-DXd)
 * Patritumab deruxtecan (HER3-DXd)
 * VN-0102
 * Valemetostat
 * DS-1647

Thank you for your time and your feedback! Mary Gaulke (talk) 18:09, 20 May 2021 (UTC)
 * I'll look at this tomorrow when I have more time. ··· 日本穣 ·  投稿  · Talk to Nihonjoe ·  Join WP Japan ! 23:39, 14 June 2021 (UTC)
 * Updated through the products list. Note that Wikipedia is not for listing every product for every company. I've left the list as is and added a reference link to the company product list. ··· 日本穣 ·  投稿  · Talk to Nihonjoe ·  Join WP Japan ! 17:38, 15 June 2021 (UTC)
 * Okay, I think I've gotten all of them. ··· 日本穣 ·  投稿  · Talk to Nihonjoe ·  Join WP Japan ! 17:55, 15 June 2021 (UTC)
 * Thanks so much for your help! Mary Gaulke (talk) 13:50, 16 June 2021 (UTC)

2023 COI edit requests
Hi! As noted above, I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I have some new requests for this article:


 * In the infobox, update
 * key_people   = Sunao Manabe (Representative Director, and President)

Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
 * num_employees = 15,348 (as of March 2020)
 * to
 * key_people   = Sunao Manabe (Representative Director and CEO)

Hiroyuki Okuzawa (Representative Director, President and COO)

Ken Keller (President and CEO, Daiichi Sankyo, Inc.)

Ken Takeshita, MD (Global Research & Development Chief, Daiichi Sankyo, Inc.)
 * num_employees = 17,435 (as of May 2023)


 * In the infobox, update
 * revenue      = ▲ $ 9.028 billion USD (FY 2019) (¥  981.8 billion JPY) (FY 2019)
 * net_income   = ▲ $ 1.276 billion USD (FY 2019) (¥  138.8 billion JPY) (FY 2019)
 * to
 * revenue      = ▲ $ 9.44 billion USD (FY 2022) (¥  1,278 billion JPY) (FY 2022)
 * net_income   = ▲ $ 812 million USD (FY 2022) (¥  109.2 billion JPY) (FY 2022)


 * Update
 * It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India.
 * to
 * It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
 * Plexxikon has been closed, and it seems odd to me to include the former Ranbaxy ownership in the lead.


 * Update
 * Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
 * to
 * Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan), a HER2 directed antibody-drug conjugate (ADC) and the lead ADC in the company's oncology portfolio.
 * Daiichi Sankyo's patent on Benicar expired several years ago; Cosette Pharmaceuticals now holds US sales and distribution rights. I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.


 * Move
 * The shutdown of Plexxikon was announced in 2022 as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.
 * from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).


 * Delete
 * The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
 * This sentence is outdated and superseded by subsequent information.


 * In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound quizartinib. ", delete "Phase III" – quizartinib is now approved for use in Japan and in the United States.
 * Update
 * Daiichi Sankyo developed Enhertu in cooperation with AstraZeneca,
 * to
 * Enhertu has been patented by Daiichi Sankyo and is being co-developed and co-commercialized in cooperation with AstraZeneca,


 * Add:
 * Ezharmia (valemetostat) (available only in Japan)


 * Update
 * Turalio (pexidartinib)
 * to
 * Turalio (pexidartinib) (available only in the United States)

Delete Since Daiichi Sankyo no longer holds the rights to Benicar.
 * Benicar (olmesartan medoxomil) (also sold as Benicar HCT, Azor, Olmetec, Rezaltas, Sevikar, and Tribenzor)


 * Delete
 * Valemetostat
 * Since it's now an oncology product, noted above.


 * Add
 * DS-1211
 * DS-5670 (Japan only)
 * Ifinatamab deruxtecan (I-DXd; DS-7300)
 * Raludotatug deruxtecan (R-DXd; DS-6000)

Thank you for your time! Mary Gaulke (talk) 21:14, 19 October 2023 (UTC)


 * I'm sorry, but this request needs a quick go-over before it's ready for review. There are several instances where two references are verifying the same information, which need to be consolidated into one reference. I'd also like to see Wikilinks for any key people who are not president, chairman or CEO (Wikilinks for Pipeline candidates as well) There is also the proposed text where we learn that Enhertu has been patented by Daiichi Sankyo and is being co-developed and co-commercialized in cooperation with AstraZeneca and then, later on in the text, we again discover that Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan) Why are both of these passages of text being asked to be placed/re-placed into the article? Lastly, while on the subject of Enhertu, there is a HER2 directed antibody-drug conjugate (ADC) and the lead ADC in the company's oncology portfolio which is problematic, as the phrase "lead drug in their portfolio" sounds like something ripped from the company's website, which we can do without. Thank you in advance for these changes! Regards, Spintendo  01:20, 20 October 2023 (UTC)

revised 2023 COI edit requests
Hi again – I've revised the edit requests below in response to the feedback above.


 * In the infobox, update
 * key_people   = Sunao Manabe (Representative Director, and President)

Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
 * num_employees = 15,348 (as of March 2020)
 * to
 * key_people   = Sunao Manabe (Representative Director and CEO)

Hiroyuki Okuzawa (Representative Director, President and COO)

Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
 * num_employees = 17,435 (as of May 2023)


 * In the infobox, update
 * revenue      = ▲ $ 9.028 billion USD (FY 2019) (¥  981.8 billion JPY) (FY 2019)
 * net_income   = ▲ $ 1.276 billion USD (FY 2019) (¥  138.8 billion JPY) (FY 2019)
 * to
 * revenue      = ▲ $ 9.44 billion USD (FY 2022) (¥  1,278 billion JPY) (FY 2022)
 * net_income   = ▲ $ 812 million USD (FY 2022) (¥  109.2 billion JPY) (FY 2022)


 * Update
 * It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India.
 * to
 * It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
 * Plexxikon has been closed, and it seems odd to me to include the former Ranbaxy ownership in the lead.


 * Update
 * Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
 * to
 * Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan), a HER2 directed antibody-drug conjugate (ADC) and the primary ADC in the company's oncology portfolio.
 * Daiichi Sankyo's patent on Benicar expired several years ago; Cosette Pharmaceuticals now holds US sales and distribution rights. I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.


 * Move
 * The shutdown of Plexxikon was announced in 2022 as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.
 * from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).


 * Delete
 * The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
 * This sentence is outdated and superseded by subsequent information.


 * In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound quizartinib. ", delete "Phase III" – quizartinib is now approved for use in Japan and in the United States.
 * Update
 * Daiichi Sankyo developed Enhertu in cooperation with AstraZeneca,
 * to
 * Enhertu has been patented by Daiichi Sankyo and is being co-developed and co-commercialized in cooperation with AstraZeneca,
 * Per 's feedback above, noting I'm proposing Enhertu-related text for both the lead and Acquisitions section per MOS:LEADNOTUNIQUE, specifically the guideline that the information in the lead should generally also appear in the body of the article.


 * Add:
 * Ezharmia (valemetostat) (available only in Japan)


 * Update
 * Turalio (pexidartinib)
 * to
 * Turalio (pexidartinib) (available only in the United States)

Delete Since Daiichi Sankyo no longer holds the rights to Benicar.
 * Benicar (olmesartan medoxomil) (also sold as Benicar HCT, Azor, Olmetec, Rezaltas, Sevikar, and Tribenzor)


 * Delete
 * Valemetostat
 * Since it's now an oncology product, noted above.


 * Add
 * Ifinatamab deruxtecan (I-DXd; DS-7300)

Please let me know if there's any other feedback. Thank you for your time! Mary Gaulke (talk) 13:31, 4 December 2023 (UTC)
 * ✅ The proposed Enhertu lead section was not included. The claim regarding Enhertu being "co-developed and co-commercialized" with AZ was not updated because the current wording is sufficient while the term "co-commercialized" may not be one that is easily recognized nor relevant to readers (that is, the fact that they're splitting the cost of advertising may not be relevant to all readers). Regards, Spintendo  05:20, 25 December 2023 (UTC)